The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Tumor Antigen Escape from CAR T-cell Therapy
Abstract
Emerging data from chimeric antigen receptor (CAR) T-cell trials in B-cell malignancies demonstrate that a common mechanism of resistance to this novel class of therapeutics is the emergence of tumors with loss or downregulation of the target antigen. Antigen loss or antigen-low escape is likely to emerge as an even greater barrier to success in solid tumors, which manifest greater heterogeneity in target antigen expression. Potential approaches to overcome this challenge include engineering CAR T cells to achieve multispecificity and to respond to lower levels of target antigen and more efficient induction of natural antitumor immune responses as a result of CAR-induced inflammation. In this article, we review the evidence to date for antigen escape and downregulation and discuss approaches currently under study to overcome these obstacles. Significance: Antigen escape and downregulation have emerged as major issues impacting the durability of CAR T-cell therapy. Here, we explore their incidence and ways to overcome these obstacles in order to improve clinical outcomes. Cancer Discov; 8(10); 1219–26. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“” This may reflect the relative low tumor mutational burden in B-ALL, which likely limits inherent immunogenicity of this disease (34, 42).”
BackgroundAxicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Self-citationCancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 2×
“However, additional insights regarding the pathophysiology of cytokine release syndrome (CRS) following CAR T-cell therapeutics suggest that cardiovascular collapse in this patient was more likely related to uncontrolled, systemic T-cell activation leading to fatal CRS (80).”
BackgroundSelf-citationLong-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
O’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,590
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Self-citationBrentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
Self-citationTurtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Irving, B. A., & Weiss, A. (1991) · Cell · doi:10.1016/0092-8674(91)90314-o · Cited by 805
Ali, S. A., Shi, V., Maric, I., Wang, M., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler-Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 757
Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L.-A., Finney, O., Smithers, H., Jensen, M. C., Riddell, S. R., Maloney, D. G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665547 · Cited by 749
Evidence that a Single Peptide–MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response
Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J., & Eisen, H. N. (1996) · Immunity · doi:10.1016/s1074-7613(00)80483-5 · Cited by 703
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S. A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K. K. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83416 · Cited by 677
Topp, M. S., Gökbuget, N., Zugmaier, G., Klappers, P., Stelljes, M., Neumann, S., Viardot, A., Marks, R., Diedrich, H., Faul, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.3247 · Cited by 658
Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0231 · Cited by 607
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 572
Self-citationLiu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0159 · Cited by 565
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Ruella, M., Barrett, D. M., Kenderian, S. S., Shestova, O., Hofmann, T. J., Perazzelli, J., Klichinsky, M., Aikawa, V., Nazimuddin, F., Kozlowski, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87366 · Cited by 558
Finney, H. M., Lawson, A. D. G., Bebbington, C. R., & Weir, A. N. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2791 · Cited by 546
Heczey, A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A., Grilley, B., Liu, H., Wu, M. F., Mei, Z., Gee, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.012 · Cited by 535
Gill, S., Tasian, S. K., Ruella, M., Shestova, O., Li, Y., Porter, D. L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S. A., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529537 · Cited by 489
Topp, M. S., Gökbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.-E., Klinger, M., Neumann, S. A., Horst, H. A., Raff, T., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-07-441030 · Cited by 474
Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., Nagase, F., & Kurosawa, Y. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90502-x · Cited by 429
Jacoby, E., Nguyen, S. M., Fountaine, T. J., Welp, K., Gryder, B., Qin, H., Yang, Y., Chien, C. D., Seif, A. E., Lei, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12320 · Cited by 429
Self-citationTrivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
Bielamowicz, K., Fousek, K., Byrd, T. T., Samaha, H., Mukherjee, M., Aware, N., Wu, M.-F., Orange, J. S., Sumazin, P., Man, T.-K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox182 · Cited by 425
Goff, S. L., Dudley, M. E., Citrin, D. E., Somerville, R. P., Wunderlich, J. R., Danforth, D. N., Zlott, D. A., Yang, J. C., Sherry, R. M., Kammula, U. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7220 · Cited by 407
Caruso, H. G., Hurton, L. V., Najjar, A., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K., Singh, H., Huls, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0139 · Cited by 397
Walker, A. J., Majzner, R. G., Zhang, L., Wanhainen, K., Long, A. H., Nguyen, S. M., Lopomo, P., Vigny, M., Fry, T. J., Orentas, R. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.008 · Cited by 383
Self-citationGargett, T., Yu, W., Dotti, G., Yvon, E. S., Christo, S. N., Hayball, J. D., Lewis, I. D., Brenner, M. K., & Brown, M. P. (2016) · Molecular Therapy · doi:10.1038/mt.2016.63 · Cited by 358
Davenport, A. J., Cross, R. S., Watson, K. A., Liao, Y., Shi, W., Prince, H. M., Beavis, P. A., Trapani, J. A., Kershaw, M. H., Ritchie, D. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716266115 · Cited by 351
Perna, F., Berman, S. H., Soni, R. K., Mansilla-Soto, J., Eyquem, J., Hamieh, M., Hendrickson, R. C., Brennan, C. W., & Sadelain, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.004 · Cited by 346
Li, S., Siriwon, N., Zhang, X., Yang, S., Jin, T., He, F., Kim, Y. J., Mac, J., Lu, Z., Wang, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0867 · Cited by 300
Zhao, Y., Wang, Q. J., Yang, S., Kochenderfer, J. N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900447 · Cited by 293
Sampson, J. H., Choi, B. D., Sanchez-Perez, L., Suryadevara, C. M., Snyder, D. J., Flores, C. T., Schmittling, R. J., Nair, S. K., Reap, E. A., Norberg, P. K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0709 · Cited by 291
NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma
Weiss, T., Weller, M., Guckenberger, M., Sentman, C. L., & Roth, P. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1788 · Cited by 287
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
Ruella, M., & Maus, M. V. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.003 · Cited by 285
Watanabe, K., Terakura, S., Martens, A. C., van Meerten, T., Uchiyama, S., Imai, M., Sakemura, R., Goto, T., Hanajiri, R., Imahashi, N., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402346 · Cited by 284
Braig, F., Brandt, A., Goebeler, M., Tony, H.-P., Kurze, A.-K., Nollau, P., Bumm, T., Böttcher, S., Bargou, R. C., & Binder, M. (2017) · Blood · doi:10.1182/blood-2016-05-718395 · Cited by 268
Schneider, D., Xiong, Y., Wu, D., Nӧlle, V., Schmitz, S., Haso, W., Kaiser, A., Dropulic, B., & Orentas, R. J. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0246-1 · Cited by 262
Fischer, J., Paret, C., El Malki, K., Alt, F., Wingerter, A., Neu, M. A., Kron, B., Russo, A., Lehmann, N., Roth, L., et al. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000169 · Cited by 245
Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition
Valitutti, S. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01075-x · Cited by 241
Albino, A. P., Lloyd, K. O., Houghton, A. N., Oettgen, H. F., & Old, L. J. (1981) · The Journal of experimental medicine · doi:10.1084/jem.154.6.1764 · Cited by 207
Lynn, R. C., Poussin, M., Kalota, A., Feng, Y., Low, P. S., Dimitrov, D. S., & Powell, D. J. (2015) · Blood · doi:10.1182/blood-2014-11-612721 · Cited by 182
Harris, D. T., Hager, M. V., Smith, S. N., Cai, Q., Stone, J. D., Kruger, P., Lever, M., Dushek, O., Schmitt, T. M., Greenberg, P. D., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700236 · Cited by 182
Shalabi, H., Kraft, I. L., Wang, H.-W., Yuan, C. M., Yates, B., Delbrook, C., Zimbelman, J. D., Giller, R., Stetler-Stevenson, M., Jaffe, E. S., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.183459 · Cited by 170
Lineage Switch in MLL‐Rearranged Infant Leukemia Following CD19‐Directed Therapy
Rayes, A., McMasters, R. L., & O'Brien, M. M. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.25953 · Cited by 168
Aldoss, I., Song, J., Stiller, T., Nguyen, T., Palmer, J., O'Donnell, M., Stein, A. S., Marcucci, G., Forman, S., & Pullarkat, V. (2017) · American Journal of Hematology · doi:10.1002/ajh.24783 · Cited by 164
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.002 · Cited by 150
Self-citationMaude, S. L., Teachey, D. T., Rheingold, S. R., Shaw, P. A., Aplenc, R., Barrett, D. M., Barker, C. S., Callahan, C. A., Frey, N. V., Nazimuddin, F., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3011 · Cited by 149
Slaney, C. Y., von Scheidt, B., Davenport, A. J., Beavis, P. A., Westwood, J. A., Mardiana, S., Tscharke, D. C., Ellis, S. L., Prince, H. M., Trapani, J. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1860 · Cited by 127
Lee, D. W., Stetler‐Stevenson, M., Yuan, C. M., Shah, N. N., Delbrook, C., Yates, B., Zhang, H., Zhang, L., Kochenderfer, J. N., Rosenberg, S. A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.218.218 · Cited by 122
Self-citationEvolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells
Evans, A. G., Rothberg, P. G., Burack, R., Huntington, S. F., Porter, D. L., Friedberg, J. W., & Liesveld, J. L. (2015) · British Journal of Haematology · doi:10.1111/bjh.13562 · Cited by 105
Tanaka, M., Tashiro, H., Omer, B. A., Lapteva, N., Ando, J., Ngo, M. C., Mehta, B., Dotti, G., Kinchington, P. R., Leen, A. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2138 · Cited by 104
CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies
Martyniszyn, A., Krahl, A.-C., Andre, M. C., Hombach, A. A., & Abken, H. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.126 · Cited by 98
Nagel, I., Bartels, M., Duell, J., Oberg, H., Ussat, S., Bruckmueller, H., Ottmann, O. G., Pfeifer, H., Trautmann, H., Gökbuget, N., et al. (2017) · Blood · doi:10.1182/blood-2017-05-782888 · Cited by 97
Yu, H., Sotillo, E., Harrington, C. T., Wertheim, G. B. W., Paessler, M. E., Maude, S. L., Rheingold, S. R., Grupp, S. A., Thomas‐Tikhonenko, A., & Pillai, V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24594 · Cited by 94
Hombach, A. A., Görgens, A., Chmielewski, M. M., Murke, F., Kimpel, J., Giebel, B., & Abken, H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.82 · Cited by 82
Zoghbi, A., Stadt, U. Z., Winkler, B., Müller, I., & Escherich, G. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26594 · Cited by 66
Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts
Cui, Y., Zhang, H., Meadors, J. L., Poon, R., Guimond, M., & Mackall, C. L. (2009) · Blood · doi:10.1182/blood-2009-03-212134 · Cited by 63
Self-citationBiberacher, V., Decker, T. W., Oelsner, M., Wagner, M. M., Bogner, C., Schmidt, B., Kreitman, R. J., Peschel, C., Pastan, I. H., Büschenfelde, C. M. Z., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.049155 · Cited by 45
Hegde, M. G., DeRenzo, C. C., Zhang, H., Mata, M., Gerken, C. P., Shree, A., Yi, Z., Brawley, V. S., Dakhova, O., Wu, M.-F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.10508 · Cited by 42
Gardner, R., Finney, O. C., Smithers, H. M., Leger, K. J., Annesley, C., Summers, C. N., Brown, C., Mgebroff, S., Lindgren, C. G., Spratt, K., et al. (2016) · Blood · doi:10.1182/blood.v128.22.219.219 · Cited by 40
Brudno, J. N., Shi, V., Stroncek, D., Pittaluga, S., Kanakry, J. A., Curtis, L. M., Gea‐Banacloche, J., Pavletic, S. Z., Bagheri, M. H., Rose, J. J., et al. (2016) · Blood · doi:10.1182/blood.v128.22.999.999 · Cited by 30
Huang, L., Wang, N., Li, C., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.846.846 · Cited by 20
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
c-Jun overexpression in CAR T cells induces exhaustion resistance
Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1805-z · Cited by 891
Self-citationMajzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., Rietberg, S. P., Linde, M. H., Xu, P., Rota, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0432 · Cited by 681
Self-citation
Metadata
- Authors
- Majzner, R. G., & Mackall, C. L.
- Venue
- Cancer Discovery
- Published
- 2018-10-01
- Volume
- 8
- Issue
- 10
- Pages
- 1219-1226
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2888063816
- Cited by
- 1,183
- References
- 81
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.